Does toripalimab plus anlotinib maintenance show promise for extensive-stage small-cell lung cancer?
For extensive-stage small-cell lung cancer (ES-SCLC), maintenance therapy after initial chemotherapy aims to delay progression and extend survival. A recent phase II trial tested combining the PD-1 inhibitor toripalimab with the anti-angiogenic drug anlotinib as maintenance. The results are promising, with a median overall survival of about 23 months, but the study was small and single-arm, so larger trials are needed to confirm the benefit.
What the research says
A multi-center phase II trial (NCT04363255) enrolled 20 patients with ES-SCLC who had disease control after first-line platinum-etoposide chemotherapy. They received maintenance toripalimab (240 mg every 3 weeks) plus anlotinib (12 mg orally on days 1-14 of each 21-day cycle) until progression or unacceptable toxicity 29. The median progression-free survival (PFS) from the start of maintenance was 8.18 months, and median overall survival (OS) reached 23.05 months 29. These outcomes compare favorably with historical data for ES-SCLC, where median OS is typically around 10-12 months with chemotherapy alone. Preclinical experiments showed that anlotinib increased PD-L1 expression on SCLC cells and activated Notch signaling, which may enhance the anti-tumor immune response and suppress neuroendocrine differentiation 29. Broader meta-analyses confirm that adding PD-1/PD-L1 inhibitors to platinum-etoposide improves OS (HR 0.74) and PFS (HR 0.68) in first-line ES-SCLC 34, and the toripalimab-anlotinib combination builds on this by targeting both immune checkpoints and tumor vasculature.
What to ask your doctor
- Is maintenance therapy with toripalimab and anlotinib an option for my ES-SCLC after first-line chemo?
- What are the potential side effects of this combination, and how are they managed?
- How does the survival data from this phase II trial compare to other maintenance options?
- Are there any ongoing clinical trials testing toripalimab plus anlotinib that I might be eligible for?
- What is the evidence for using anlotinib in SCLC, and does it interact with other medications I take?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.